Bristol Is Not Bayer: Primary Care Strategy Is “Different, Not Exit”
Executive Summary
Bristol-Myers Squibb is trying a "different model" for primary care, but the company has no intention of exiting the market, CEO Peter Dolan told the Bear Stearns conference in New York Sept. 13
You may also be interested in...
Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget
Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said
Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget
Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said
Bristol submits muraglitazar, abatacept to FDA
Bristol-Myers Squibb submits muraglitazar NDA for treatment of type-2 diabetes to FDA. Bristol and Merck will co-market the product (1"The Pink Sheet" May 3, 2004, p. 15). Bristol also submitted the non-clinical and clinical sections of the abatacept BLA for rheumatoid arthritis under FDA's "continuous marketing application" program. The remaining sections will be completed in early 2005, the company said. The firm had said the full application for abatacept would be submitted before the end of 2004 and a supplemental BLA would follow with manufacturing changes (2"The Pink Sheet" Sept. 20, 2004, p. 29)...